# US 2018/0022755 A1 · Bicyclic pyridine compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022755 A1
- Document ID: US20180022755A1
- Status: Published application
- Kind: A1
- Application number: 15/551,222
- Filed: 2015-11-27
- Published: 2018-01-25
- Earliest claimed: 2015-03-09
- Assignees: Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
- Applicants: Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
- Inventors: Kenichi KAWAGUCHI; Akihiro ISHIHATA; Akira KANAI; Yusuke INAGAKI; Masashi HIRAMOTO; Kentaro ENJO; Hajime TAKAMATSU
- Web page: https://patentgrep.com/patent/US20180022755A1

## CPC

- C07D 491/048: the oxygen-containing ring being five-membered
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-(bi-cyclic pyridylmethyl)-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production. The present invention therefore provides compounds expected to be used as an agent for treating nocturia based on P-LAP inhibition.

## Claims

### Claim at position 1

1: A compound represented by Formula (I) or a salt thereof:
wherein:
X is O or S;
a dotted line is a single bond or a double bond;
R1 is lower alkyl which optionally has one to four substituents selected from the Group G1, cycloalkyl which optionally has one to five substituents selected from the Group G2, or -lower alkylene-(cycloalkyl which optionally has one to five substituents selected from the Group G2);
R2 and R5 are the same or different from each other, and are H, lower alkyl or cycloalkyl;
R3 is -lower alkylene-X3-lower alkyl, -lower alkylene-X3-lower alkylene-(cycloalkyl which optionally has one to five substituents selected from the Group G2), -lower alkylene-(cycloalkyl which optionally has one to five substituents selected from the Group G2), or -lower alkylene-X3-(cycloalkyl which optionally has one to five substituents selected from the Group G2);
X3 is O or S(O)n, wherein n is 0, 1, or 2;
R4 is OH, NH2, or —O-lower alkyl and R6 is H; or R4 and R6 are linked to each other to form, together with —C(═O)—C—O— to which they are attached, 2,2-di(lower alkyl)-4-oxo-1,3-dioxolane-5,5-diyl;
the Group G1 consists of halogen, OH, —O-lower alkyl, —S-lower alkyl, and —O-(lower halogenoalkyl); and
the Group G2 consists of lower alkyl, halogen, lower halogenoalkyl, OH, —O-lower alkyl, —S-lower alkyl, and —O-lower halogenoalkyl.

### Claim at position 2 (depends on 1)

2: The compound or a salt thereof according to claim 1, wherein R4 is OH, NH2, or —O-lower alkyl and R6 is H.

### Claim at position 3 (depends on 2)

3: The compound or a salt thereof according to claim 2, wherein X is O, and a dotted line is a single bond or a double bond; or X is S, and a dotted line is a double bond.

### Claim at position 4 (depends on 3)

4: The compound or a salt thereof according to claim 3, wherein:
R1 is lower alkyl which optionally has one to four substituents selected from the group consisting of halogen, OH, and —O-lower alkyl; cycloalkyl which is optionally substituted by one to two lower alkyls; or -lower alkylene-(cycloalkyl which is optionally substituted by one to two lower alkyls);
R3 is -lower alkylene-X3-lower alkyl, -lower alkylene-X3-lower alkylene-(cycloalkyl which is optionally substituted by one to two lower alkyls), -lower alkylene-(cycloalkyl which is optionally substituted by one to two lower alkyls), or -lower alkylene-X3-(cycloalkyl which is optionally substituted by one to two lower alkyls); and
R2 and R5 are the same or different from each other, and are H or lower alkyl.

### Claim at position 5 (depends on 4)

5: The compound or a salt thereof according to claim 4, wherein:
R1 is lower alkyl which optionally has one to four substituents selected from the group consisting of halogen and OH; cycloalkyl; or -lower alkylene-cycloalkyl; and
R3 is -lower alkylene-S(O)n-lower alkyl, -lower alkylene-O-lower alkylene-cycloalkyl, -lower alkylene-S-lower alkylene-cycloalkyl, -lower alkylene-cycloalkyl, or -lower alkylene-S-cycloalkyl.

### Claim at position 6 (depends on 5)

6: The compound or a salt thereof according to claim 5, wherein R1 is lower alkyl, cycloalkyl, or -lower alkylene-cycloalkyl; R3 is -lower alkylene-S-lower alkyl, -lower alkylene-O-lower alkylene-cycloalkyl, -lower alkylene-S-lower alkylene-cycloalkyl, -lower alkylene-cycloalkyl, or -lower alkylene-S-cycloalkyl; R2 is H or lower alkyl; R5 is H; and R4 is OH.

### Claim at position 7 (depends on 6)

7: The compound or a salt thereof according to claim 6, wherein X is O, and a dotted line is a double bond; R1 is lower alkyl, or -lower alkylene-cycloalkyl; and R3 is -lower alkylene-S-lower alkyl, or -lower alkylene-cycloalkyl.

### Claim at position 8 (depends on 2)

8: The compound or a salt thereof according to claim 2, wherein X is O, and a dotted line is a double bond.

### Claim at position 9 (depends on 1)

9: The compound or a salt thereof according to claim 1, which is a compound selected from the group consisting of the following compounds, or a salt thereof:
(2R,3R)-3-amino-2-{[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl}-4-(ethylsulfanyl)-2-hydroxybutanoic acid,
(2R,3S)-3-amino-5-cyclopropyl-2-{[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl}-2-hydroxypentanoic acid,
(2R,3R)-3-amino-2-{[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl}-2-hydroxy-4-(methylsulfanyl)butanoic acid, and
(2R,3R)-3-amino-2-[(2-butyl-7-methylfuro[3,2-c]pyridin-4-yl)methyl]-2-hydroxy-4-(methylsulfanyl)butanoic acid.

### Claim at position 10 (depends on 1)

10: A pharmaceutical composition comprising the compound or a salt thereof according to claim 1.

### Claim at position 11 (depends on 10)

11: The pharmaceutical composition according to claim 10, which is an agent for treating nocturia.

### Claim at position 12 (depends on 1)

12: A pharmaceutical composition comprising the compound or a salt thereof according to claim 1 and an excipient.

### Claim at position 13

13-15. (canceled)

### Claim at position 14 (depends on 1)

16: A method of treating nocturia comprising administering an effective amount of the compound or a salt thereof according to claim 1 to a subject.

### Claim at position 15 (depends on 9)

17: The compound or a salt thereof according to claim 9, which is (2R,3R)-3-amino-2-{[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl}-4-(ethylsulfanyl)-2-hydroxybutanoic acid or a salt thereof.

### Claim at position 16 (depends on 9)

18: The compound or a salt thereof according to claim 9, which is (2R,3S)-3-amino-5-cyclopropyl-2-{[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl}-2-hydroxypentanoic acid or a salt thereof.

### Claim at position 17 (depends on 9)

19: The compound or a salt thereof according to claim 9, which is (2R,3R)-3-amino-2-{[2-(2-cyclopropylethyl)furo[3,2-c]pyridin-4-yl]methyl}-2-hydroxy-4-(methylsulfanyl)butanoic acid or a salt thereof.

### Claim at position 18 (depends on 9)

20: The compound or a salt thereof according to claim 9, which is (2R,3R)-3-amino-2-[(2-butyl-7-methylfuro[3,2-c]pyridin-4-yl)methyl]-2-hydroxy-4-(methylsulfanyl)butanoic acid or a salt thereof.
